First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND

Release time:Feb 27, 2023

Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its IND application of its self-developed 9MW3811 injection for tumor and pulmonary fibrosis has been approved by the Therapeutic Goods Administration (TGA) in Australia. 9MW3811 is the first IL-11 targeting monoclonal antibody approved to clinical study at present.

9MW3811 is an innovative humanized monoclonal antibody against IL-11, which can bind IL-11 through high affinity and effectively block the activation of IL-11 downstream signal pathway being developed for fibrosis and oncology.

20230228172800964199.jpgAnti-tumor mechanism of 9MW3811

20230228172800315917.jpgAnti-fibrosis mechanism of 9MW3811

9MW3811 is first IL-11-targeting monoclonal antibody and first non recombinant protein drug candidate targeting IL-11 approved to clinical study as well.